{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Choueiri TK"],"funding":["NCATS NIH HHS","NIMHD NIH HHS","NCI NIH HHS"],"pagination":["100445"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9925160"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19"],"pubmed_abstract":["<h4>Background</h4>Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to evaluate the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines.<h4>Methods</h4>We evaluated the clinical characteristics of patients with cancer who developed breakthrough infections using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; NCT04354701). Analysis was restricted to patients with laboratory-confirmed SARS-CoV-2 diagnosed in 2021 or 2022, to allow for a contemporary unvaccinated control population; potential differences"],"journal":["Lancet regional health. Americas"],"pubmed_title":["Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium."],"pmcid":["PMC9925160"],"funding_grant_id":["P50 MD017341","P30 CA046592","P30 CA068485","R21 CA242044","T32 CA236621","UL1 TR001425","UL1 TR000445"],"pubmed_authors":["Singh SRK","de Lima Lopes G","Yared F","Gatson NTN","Hsu CY","O'Connor TE","Labaki C","Schmidt AL","Vikas P","Del Prete S","Nanchal R","Griffiths EA","Klein EJ","Singh H","Faller B","Shyr Y","Mavromatis BH","Zaren HA","Puc M","Wu U","Dutra MS","Rubinstein SM","Joshi M","Jani C","Farmakiotis D","Wise-Draper TM","Mishra S","Bakouny Z","Halabi S","Weissmann LB","Rivera DR","Quinn R","Nonato TK","Russell K","Choueiri TK","Blau S","Berg S","Friese CR","Reuben DY","Hwang C","Accordino MK","Panagiotou OA","Warner JL","McKay RR"],"additional_accession":[]},"is_claimable":false,"name":"Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.","description":"<h4>Background</h4>Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to evaluate the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines.<h4>Methods</h4>We evaluated the clinical characteristics of patients with cancer who developed breakthrough infections using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; NCT04354701). Analysis was restricted to patients with laboratory-confirmed SARS-CoV-2 diagnosed in 2021 or 2022, to allow for a contemporary unvaccinated control population; potential differences","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-28T20:40:53.511Z","creation":"2024-11-20T11:01:02.222Z"},"accession":"S-EPMC9925160","cross_references":{"pubmed":["36818595"],"doi":["10.1016/j.lana.2023.100445"]}}